IP Library Granted Patent US 8,492,097
Granted Patent B2
US 8,492,097 · App. 11/409,600 · Granted Jul 23, 2013

Compositions and methods for human metapneumovirus monoclonal antibodies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,492,097
App. No.
11/409,600
Granted
Jul 23, 2013
Kind
B2
Abstract

The present invention discloses specific human metapneumovirus monoclonal antibodies. The antibody is at least two-fold less reactive with non-human metapneumoviruses including, but not limited to, respiratory viruses or avian metapneumoviruses. Further, the antibody is at least two-fold more reactive with a human metapneumovirus (i.e., for example, Type A or Type B) than with non-human metapneumoviruses including, but not limited to, respiratory viruses or avian metapneumoviruses. Consequently, these novel antibodies are useful as a clinical diagnostic agent, especially when using fresh nasopharengeal aspirates. The invention also contemplates numerous diagnostic platforms that together with the novel antibodies can support economical, fast, and highly selective detection and identification of clinical inoculum samples.

Claims (26)

1. A human metapneumovirus monoclonal antibody panel, comprising a first monoclonal antibody produced by the mouse spleen hybridoma clone C2C 10, a second monoclonal antibody produced by the mouse spleen hybridoma clone F4A1, and a third monoclonal antibody produced by the mouse spleen hybridoma clone CB7F3.

2. The panel of claim 1 , wherein said panel further comprises a respiratory cell sample.

3. The panel of claim 1 , wherein said first, second, and third antibodies are fluorescently labeled.

4. A method of detecting human metapneumovirus, comprising:

a) providing

i) a human metapneumovirus monoclonal antibody panel, comprising a first monoclonal antibody produced by the mouse spleen hybridoma clone C2C10, a second monoclonal antibody produced by the mouse spleen hybridoma clone F4A1, and a third monoclonal antibody produced by the mouse spleen hybridoma clone CB7F3

ii) a biological sample and

iii) a diagnostic platform capable of detecting binding between antibody and sample

b) introducing said biological sample using said diagnostic platform under conditions such that said at least one monoclonal antibody interacts with said sample and

c) detecting binding of at least one monoclonal antibody, wherein binding indicates detection of human metapneumovirus.

5. The method of claim 4 , wherein said monoclonal antibodies are fluorescently labeled.

6. The method of claim 5 , wherein said wherein said diagnostic platform is a direct immunofluorescence assay.

7. The method of claim 4 , wherein said diagnostic platform comprises a cell infection assay.

8. The method of claim 7 , wherein said assay comprises introducing the biological sample into a culture of tMK cells, wherein said tMK cells are contained within a plurality of well plates.

9. The method of claim 8 , further comprising detecting the appearance of cytopathic effects within said tMK cells.

10. The method of claim 4 , wherein said biological sample is concentrated using an elution electrophoresis system.

11. The method of claim 10 , wherein said elution electrophoresis system comprises a porous material under the influence of an electrical field.

12. The method of claim 11 , wherein said porous material is selected from the group consisting of dextran, cellulose, acrylamide, polymeric particles, and silica.

13. The method of claim 4 , wherein said diagnostic platform comprises a solid support.

14. The method of claim 13 , before step (b), binding said antibody to said solid support.

15. The method of claim 13 , wherein said solid support comprises a test strip.

16. The method of claim 15 , wherein said test strip is attached to a dipstick.

17. The method of claim 16 , wherein said dipstick comprises compounds selected from the group consisting of radioactive tracers, enzymes, colloidal metals, and substrates.

18. The method of claim 4 , wherein said diagnostic platform comprises a micro fluidic device.

19. The method of claim 18 , wherein said microfluidic device comprises a ferrofluid, wherein said antibodies are attached to said ferrofluid.

20. The method of claim 18 , wherein said microfluidic device comprises at least one microchannel in fluidic communication with at least one microchamber.

Assignments (10)
SECURITY AGREEMENT Recorded Aug 22, 2025
From: CRIMSON INTERNATIONAL ASSETS LLC; MICRO TYPING SYSTEMS, INC.; ORTHO-CLINICAL DIAGNOSTICS, INC.; QUIDEL CARDIOVASCULAR INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 072526/0643 →
RELEASE (REEL 060220 / FRAME 0711) Recorded Aug 22, 2025
From: BANK OF AMERICA, N.A.
To: QUIDEL CORPORATION; BIOHELIX CORPORATION; DIAGNOSTIC HYBRIDS, INC.; QUIDEL CARDIOVASCULAR INC.; ORTHO-CLINICAL DIAGNOSTICS, INC.; CRIMSON U.S. ASSETS LLC; CRIMSON INTERNATIONAL ASSETS LLC; MICRO TYPING SYSTEMS, INC.
Reel/Frame 072577/0536 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2024
From: DIAGNOSTICS HYBRIDS, INC.
To: ORTHO-CLINICAL DIAGNOSTICS, INC.
Reel/Frame 068657/0748 →
RELEASE OF SECURITY INTEREST Recorded May 31, 2022
From: BANK OF AMERICA, N.A.
To: QUIDEL CORPORATION
Reel/Frame 060220/0649 →
SECURITY AGREEMENT Recorded May 31, 2022
From: QUIDEL CORPORATION; BIOHELIX CORPORATION; DIAGNOSTIC HYBRIDS, INC.; QUIDEL CARDIOVASCULAR INC.; ORTHO-CLINICAL DIAGNOSTICS, INC.; CRIMSON U.S. ASSETS LLC; CRIMSON INTERNATIONAL ASSETS LLC; MICRO TYPING SYSTEMS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 060220/0711 →
SECURITY INTEREST Recorded Oct 6, 2017
From: QUIDEL CORPORATION
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 044141/0686 →
CHANGE OF ADDRESS Recorded Jan 12, 2017
From: DIAGNOSTIC HYBRIDS, INC.
To: DIAGNOSTIC HYBRIDS, INC.
Reel/Frame 041351/0846 →
NOTICE OF RELEASE OF GRANT OF PATENT SECURITY INTEREST Recorded Dec 1, 2016
From: BANK OF AMERICA, N.A., AS AGENT
To: DIAGNOSTIC HYBRIDGS, INC.
Reel/Frame 040788/0200 →
GRANT OF PATENT SECURITY INTEREST Recorded Feb 22, 2010
From: DIAGNOSTIC HYBRIDS, INC.
To: BANK OF AMERICA, N.A., AS AGENT
Reel/Frame 023963/0897 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2006
From: GERNA, GIUSEPPE; SARASINI, ANTONELLA; REVELLO, MARIA GRAZIA
To: DIAGNOSTIC HYBRIDS, INC.
Reel/Frame 018074/0575 →